The Frazier Life Sciences team invests in and builds companies developing and commercializing novel therapeutics.

500+

Collective years of investing and operational experience

100

Portfolio companies

61

M&A and IPOs

30

FDA approved drugs since 2010

Selected M&A and IPOs

Acquired by AstraZeneca in 2016
IPO in 2020 (NASDAQ:ARQT)
IPO in 2014; Acquired by Roche in 2018
NASDAQ: IOVA
IPO in 2020 (NASDAQ:PASG)
IPO in 2019 (NASDAQ: PHAT)
Acquired by CutisPharma in 2019
IPO in 2020 (NASDAQ: PCVX)

Life Sciences News

Frazier Life Sciences Team

Frazier Healthcare Partners Adds Highly Experienced Investor to Life Sciences Team

Frazier Life Sciences Team

Frazier Healthcare Partners Announces Multiple Promotions on its Life Sciences Team

Frazier Lifesciences Acquisition Corporation

Frazier Lifesciences Acquisition Corporation Announces Pricing of Upsized $120 Million Initial Public Offering

Frazier Life Sciences Team

Frazier Healthcare Partners Adds Two Senior R&D Leaders to Life Sciences Team

View All News